{"entities":{"Q49350":{"pageid":39723,"ns":120,"title":"Item:Q49350","lastrevid":205338,"modified":"2026-08-13T19:43:39Z","type":"item","id":"Q49350","labels":{"mul":{"language":"mul","value":"MG52.02"},"pt-br":{"language":"pt-br","value":"Mycobacterium tuberculosis extensivamente resistente a medicamentos"},"en":{"language":"en","value":"Extensively drug-resistant mycobacterium tuberculosis"}},"descriptions":{"pt-br":{"language":"pt-br","value":"Micobact\u00e9rias tuberculosas extensivamente resistentes a medicamentos s\u00e3o resistentes a pelo menos quatro dos principais medicamentos anti-TB. As micobact\u00e9rias XDR-TB s\u00e3o resistentes aos dois medicamentos anti-TB mais poderosos, isoniazida e rifampicina, tamb\u00e9m conhecida como multirresist\u00eancia a medicamentos, al\u00e9m da resist\u00eancia a qualquer uma das fluoroquinolonas (como levofloxacina ou moxifloxacina) e a pelo menos uma das tr\u00eas drogas injet\u00e1veis de segunda linha (amicacina, capreomicina ou canamicina)."},"en":{"language":"en","value":"Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin)."}},"aliases":{},"claims":{"P68":[{"mainsnak":{"snaktype":"value","property":"P68","hash":"0a707b5cff54133afbafed4ec87d791ce73ec73b","datavalue":{"value":"https://id.who.int/icd/entity/1947911830","type":"string"},"datatype":"url"},"type":"statement","id":"Q49350$13D23803-84AB-40F1-9F1D-126F73A2C1CF","rank":"normal"}],"P67":[{"mainsnak":{"snaktype":"value","property":"P67","hash":"691addb0d1873ec5389a110dcaa38d28a6883788","datavalue":{"value":"CID11:MG52.02","type":"string"},"datatype":"string"},"type":"statement","id":"Q49350$3B8D7BA2-87FD-4439-AEB3-83EAFBD3F949","rank":"normal"}],"P70":[{"mainsnak":{"snaktype":"value","property":"P70","hash":"87478f8d7c4d25b2268b5a5735cb9ea04ec79083","datavalue":{"value":"dki-india-MG52.02","type":"string"},"datatype":"string"},"type":"statement","id":"Q49350$3C3F2AAA-7F5F-4584-9CBC-F10D1FDB3115","rank":"normal"}],"P86":[{"mainsnak":{"snaktype":"value","property":"P86","hash":"a96031634b9f5dafddaf781bbba3adea6bb64ef4","datavalue":{"value":"Conclu\u00eddo","type":"string"},"datatype":"string"},"type":"statement","id":"Q49350$6B225F95-2E0D-4433-A9F3-4D4E5DE57B20","rank":"normal"}],"P78":[{"mainsnak":{"snaktype":"value","property":"P78","hash":"5f9b5be68b7400da549761cf15abfdbc4d1e075b","datavalue":{"value":"https://pauloleads.com.br/cases-publicos/","type":"string"},"datatype":"url"},"type":"statement","id":"Q49350$545B3395-7F27-4576-AA4B-CD3C12A3590D","rank":"normal"}],"P80":[{"mainsnak":{"snaktype":"value","property":"P80","hash":"92b8222fcbb75718504f915073a3f43bd4003d18","datavalue":{"value":{"time":"+2026-08-13T00:00:00Z","timezone":0,"before":0,"after":0,"precision":11,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q49350$F7E98D91-BD39-4F7D-ACA8-B0A14AD4E5F7","rank":"normal"}],"P89":[{"mainsnak":{"snaktype":"value","property":"P89","hash":"fbc29e5476ec71eb4a6b8b4871fa49ec57a42070","datavalue":{"value":{"entity-type":"item","numeric-id":49349,"id":"Q49349"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q49350$6F2AC295-4F21-4EA7-94CB-35167E3ACF6D","rank":"normal"}]},"sitelinks":{}}}}